Chapter 474: Chapter 274: CCTV Steps In, Support from the Liver Tumor Field

As such, this meeting gave them a chance to become better acquainted.

The two vice presidents, accompanied by their simultaneous interpreters, engaged in a cordial conversation with Wu Ting.

After offering some praise for Wu Ting, Vice President Ford got straight to the point and stated the purpose of his visit.

"Director Wu, the primary purpose of GSK’s visit is to obtain exclusive authorization in the Southern District for the fourth-generation bioresorbable polymer vascular stent and the controllable, self-expanding valve delivery system developed by your company. We also seek exclusive authorization for all subsequent product lines related to these materials and equipment..."

Ford knew this was a massive deal, so it was only natural that he had to put significant chips on the table.

"Director Wu, to demonstrate our sincerity, we are willing to support you with both capital and academic influence in your competition against Professor Edwards and his team!"

"Director Wu, if you agree, we can introduce you to the top academic authorities in cardiovascular surgery and hepatic tumor surgery in the Southern District. We can facilitate academic exchanges and clinical collaborations between you and them."

"GSK works closely with the Southern Liver Research Association and the liver center at King’s College Hospital of Yun Country. We have a long-standing partnership with their president, Professor Bellingham, who is also the hospital’s vice president..."

Steve, the vice president from Johnson & Johnson Group, expressed a similar proposition:

"Director Wu, we at the Johnson & Johnson Group would also like to obtain exclusive authorization for your research results in the Mizhou District."

"In return, we can also help you in the Southern Country to counter the Ruihui Group and Edwards’s team."

"Our group also has a good working relationship with the World Association of Thoracic and Cardiovascular Surgery. If your Hybrid Technology can lead to an expert consensus and clinical guidelines in the future, Director Wu, our group is willing to support your bid for a standing committee position, moving you up to Vice President, and eventually, President of the association!"

"In the academic sphere, we can also connect you with Professor James, the vice president of Cleveland Hospital—the leading institution for cardiovascular surgery in the Southern Country. This would facilitate collaboration and exchanges, boosting your influence!"

Listening to the overtures and earnest proposals from the two vice presidents, Wu Ting couldn’t immediately grasp the hidden machinations at play.

Steve explained to Wu Ting:

"Director Wu, our associations and academic authorities in the Southern Country might be different from those in your Jin Country. Here, all projects by medical experts and scientists are conducted with financial backing from pharmaceutical companies like ours or related investors."

"We are all deeply intertwined. We fund their research, and they, as the authorities and leaders in their fields, endorse and promote our medical devices in return. It’s a mutually beneficial relationship where we both profit and gain prestige."

"Right now, Professor Edwards’s team and Ruihui have developed Neutrino Technology. If they succeed, they’ll establish the ’International HBV-related Primary Liver Cancer Research Group’ and position Neutrino Technology as the gold standard for diagnosis and treatment, creating the industry guidelines."

"In that case, the liver cancer market would essentially be monopolized by Ruihui, which would be very detrimental to us at the Johnson & Johnson Group."

"That is why I’ve come to Jin Country—in the hopes of collaborating with you, Director Wu."

"First, our team conducted a comprehensive analysis. We believe your research in cardiovascular surgery represents a massive market. If we collaborate, we can capture a huge share of the cardiovascular field. We can then use our gains in the cardiovascular market to offset our losses in the liver cancer market."

"Furthermore, in the field of HBV-related primary liver cancer, it is still uncertain whether your team or Edwards’s team will emerge victorious."

"Thus, our collaboration can be the very tool you use to defeat Edwards’s team!"

"As you said in your declaration on Headquarter TV Station, you’re an expert in immunology and antiviral therapy. With that expertise, is it possible for you to challenge the patent for Neutrino Technology?"

"Neutrino Technology was developed by Professor Owen at the University of California, Berkeley, but Ruihui currently holds the patent."

"As long as you can withstand the pressure from Edwards in the liver cancer field, or even compete with him on equal footing, we can leverage the cardiovascular market to put pressure on Ruihui!"

"If you can truly establish clinical guidelines for your Hybrid Technology and publish the corresponding industry standards, then we’ll have the leverage to make you the President of the World Association of Thoracic and Cardiovascular Surgery."

"That would give us a commanding voice in the cardiovascular disease market. If Edwards’s Neutrino project is still not fully developed by then, our positions will be reversed. We believe Ruihui will cut their losses."

"We could even cede a portion of our cardiovascular market share to them in a forced buyout of the Neutrino Technology patent. Faced with a choice between a guaranteed slice of the cardiovascular market and an uncertain outcome in the liver cancer field, we believe Ruihui will make the logical choice. When that happens, Professor Owen from UC Berkeley will become the very blade that finishes Edwards!"

"Professor Edwards is just one of many assets backed by Ruihui. When the time comes, they will surely discard him."

"Without Neutrino Technology, Edwards’s own theory of targeted decomposition and apoptosis will have no foundation."

"At that point, on what grounds could he establish the International HBV-related Primary Liver Cancer Research Group? How could he possibly have the audacity to serve as president of the International Liver Cancer Association?"

"His Neutrino team will fall apart. His project, a castle in the sky, will come crashing down!"

Steve had become a vice president at the Johnson & Johnson Group for a reason. He was a master of academic power plays and strategic maneuvering, with every trick at his fingertips.

"Director Wu, of course, the absolute key to all this is for you to finalize the clinical guidelines for your Hybrid Technology in cardiovascular surgery—or the guidelines for a complete curative therapy for HBV-related primary liver cancer—before Edwards’s Neutrino Technology project matures and its own guidelines are established."

Steve’s plan gave Wu Ting a glimpse into the dark, treacherous underbelly of the academic world.

’Defeat Professor Edwards with the very tactics he’s so skilled at: leveraging capital and the power of academic cliques.’

Ford also expressed his clandestine support for Steve’s strategy.

"Director Wu, our partner associations and the relevant academic authorities in the Southern District will also support you when the time is right!"

If you find any errors ( broken links, non-standard content, etc.. ), Please let us know < report chapter > so we can fix it as soon as possible.